KRAS and non-small cell lung carcinoma: Based on the results of the Krystal-1 phase I clinical trial in which adagrasib showed an objective response in more than 40% of patients with locally advanced or metastatic NSCLC, adagrasib became a second FDA-approved drug for the treatment of KRAS G12C-mutated NSCLC [39].